EarningsQ2 2026 Earnings Report
DE:2YP Q2 2026 EPS Results
Actual EPS€0.04
Consensus EPS€0.03
Beat/MissBeat by +<€0.01
One Year Ago EPS€0.04
DE:2YP Q2 2026 Revenue Results
Actual Revenue€62.90M
Expected Revenue€61.66M
Beat/MissBeat by +€1.24M
YoY Revenue Growth-12.68%
Earnings Announcement Details
QuarterQ2 2026
Date08/06/2026
TimeAfter Close
Conference CallThursday, August 6, 2026
DE:2YP Upcoming Earnings
Health Catalyst's next earnings date is estimated for November 5, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
DE:2YP Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Neutral
The call communicated meaningful strategic progress: a completed divestiture that eliminated debt and interest costs, cost reductions via Project Nexus, a Q2 revenue beat and adjusted EBITDA at the high end of guidance, and continued investments in technology and AI. However, the near-term picture is constrained by the loss of Vitalware's revenue/EBITDA contribution, persistent migration-related churn and at-risk ARR, margin pressure from dual operating costs during migrations, and a lowered full-year revenue/EBITDA outlook. Management frames these as deliberate, multiyear transformation actions that improve the capital structure and position the company for long-term growth while acknowledging short-term revenue and margin headwinds.Company Guidance
Revenue Beat in Q2
Total revenue of $70.5 million for Q2 2026 exceeded the high end of guidance ($68M–$70M) by $0.5M (approximately +0.7%).
Adjusted EBITDA at High End
Adjusted EBITDA was $9.9 million in Q2, coming in at the high end of the guided range ($9M–$10M).
Gross Margin Improvement (Overall)
Adjusted gross margin improved to 51% in Q2 2026 from 50% in the prior year period (increase of ~1 percentage point).
Operating Expense Reduction and Project Nexus Progress
Adjusted operating expenses fell to $25.9 million (37% of revenue) from $30.6 million (38% of revenue) year-over-year, a reduction of $4.7M or ~15.4%. Management reports Project Nexus is on track and expected to exceed original savings targets, with additional OpEx reductions from the Vitalware carve-out to follow.
Balance Sheet Improvement and Debt Elimination
Closed Vitalware divestiture for $147M ($145.5M net proceeds) and used proceeds plus cash to fully retire approximately $160M of credit facility debt, resulting in a debt-free pro forma position and elimination of ~ $19M annual GAAP interest expense (approx. $16.5M of annual cash interest savings based on H1 2026).
Liquidity Position
Ended the quarter with ~$103.4M in cash, cash equivalents and short-term investments and pro forma cash of ~ $82M after the Vitalware transaction and credit facility repayment.
Services and Technology Revenue Mix and Margin Trajectory
Technology revenue was $48.8M and professional services revenue was $21.7M. Management expects overall adjusted gross margin to trend higher over the long term as revenue mix shifts towards technology, with adjusted technology gross margin expected in the low 60s over the full year.
Reduction in Stock-Based Compensation
Expect stock-based compensation to be down significantly in 2026 in absolute dollars and to be in the mid-single digits as a percentage of revenue for the full year.
DE:2YP Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed